FY2026 Earnings Forecast for AMLX Issued By HC Wainwright

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Amylyx Pharmaceuticals in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst A. Ghosh anticipates that the company will post earnings per share of ($1.51) for the year. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ Q4 2026 earnings at ($0.36) EPS, FY2027 earnings at ($1.42) EPS, FY2028 earnings at ($0.99) EPS, FY2029 earnings at $3.06 EPS and FY2030 earnings at $6.13 EPS.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38).

A number of other equities research analysts have also recently issued reports on the company. Stifel Nicolaus set a $45.00 price objective on Amylyx Pharmaceuticals in a research note on Thursday, November 5th. Mizuho increased their target price on shares of Amylyx Pharmaceuticals from $38.00 to $39.00 and gave the stock an “outperform” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Tuesday, November 3rd. Guggenheim lifted their target price on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Finally, Citigroup boosted their price target on shares of Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, October 15th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amylyx Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $43.71.

Amylyx Pharmaceuticals Trading Up 2.3%

AMLX stock opened at $30.91 on Monday. Amylyx Pharmaceuticals has a fifty-two week low of $10.83 and a fifty-two week high of $41.14. The stock has a fifty day moving average of $29.85 and a 200-day moving average of $20.55.

Insider Activity

In other Amylyx Pharmaceuticals news, Director M Jr sold 30,000 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $27.70, for a total value of $831,000.00. Following the sale, the director directly owned 782,881 shares in the company, valued at $21,685,803.70. This represents a 3.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Camille Bedrosian sold 10,028 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $32.40, for a total transaction of $324,907.20. Following the completion of the transaction, the insider directly owned 278,064 shares of the company’s stock, valued at approximately $9,009,273.60. The trade was a 3.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 60,374 shares of company stock valued at $1,815,257. 10.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. KBC Group NV purchased a new position in Amylyx Pharmaceuticals during the first quarter worth about $26,000. GAMMA Investing LLC raised its holdings in shares of Amylyx Pharmaceuticals by 163.0% in the 3rd quarter. GAMMA Investing LLC now owns 1,139 shares of the company’s stock valued at $33,000 after acquiring an additional 706 shares in the last quarter. State of Wyoming purchased a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at about $40,000. Sterling Capital Management LLC raised its holdings in shares of Amylyx Pharmaceuticals by 958.5% in the 3rd quarter. Sterling Capital Management LLC now owns 3,419 shares of the company’s stock valued at $99,000 after acquiring an additional 3,096 shares in the last quarter. Finally, Hantz Financial Services Inc. purchased a new stake in shares of Amylyx Pharmaceuticals in the 3rd quarter valued at about $130,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.